Repare Therapeutics Inc. (RPTX)

Data as of Jan 30, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch RPTX

See up to 3 months of RPTX. The 7-day demo opens the 1M and 3M ranges and puts RPTX on your watchlist.

Latest RPTX insider trades

BVF PARTNERS L P - 10% Owner
Other5,309,432 sh
Jan 28, 2026
BVF PARTNERS L P - 10% Owner
Other4,308,573 sh
Jan 28, 2026
BVF PARTNERS L P - 10% Owner
Other

About Repare Therapeutics Inc. (RPTX)

Repare Therapeutics Inc. is an SEC registrant, filing under CIK 0001808158, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.

Sector: Health Care

SEC filings for RPTX on EDGAR

RPTX Form 4 activity by transaction type, last 90 days

No Form 4 activity for RPTX in the last 90 days.

RPTX insider transactions (Form 4)

6 Form 4 filings on record, the earliest from Jan 29, 2026, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Jan 28, 2026	BVF PARTNERS L P - 10% Owner	Other	Common Shares, no par value	5,309,432	-^{footnote F6}	-
Jan 28, 2026	BVF PARTNERS L P - 10% Owner	Other	Common Shares, no par value	4,308,573	-^{footnote F6}	-
Jan 28, 2026	BVF PARTNERS L P - 10% Owner	Other	Common Shares, no par value	548,938	-^{footnote F6}	-
Footnote F6 (price): The Reporting Persons received the following in exchange for each Common Share of the Issuer disposed of in connection with the Merger: $2.20 in cash per Common Share and one contingent value right per Common Share for potential cash payments.
Jan 28, 2026	Carol Schafer	Derivative	Common Shares	8,000^{footnote F1}	-^{footnote F2}	-
Jan 28, 2026	Carol Schafer	Derivative	Stock Option (right to buy)	37,941	$0.00	-
Footnote F1 (shares): Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.
Jan 28, 2026	Ann D. Rhoads	Derivative	Common Shares	4,000^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.
Jan 28, 2026	Thomas Civik	Derivative	Common Shares	7,500^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.
Jan 28, 2026	Steve Forte - Officer	Derivative	Common Shares	56,786^{footnote F1,F2}	-^{footnote F3}	-
Jan 28, 2026	Steve Forte - Officer	Derivative	Employee Stock Option (right to buy)	200,000	$0.00	-
Jan 28, 2026	Steve Forte - Officer	Derivative	Employee Stock Option (right to buy)	85,000	$0.00	-
Jan 28, 2026	Steve Forte - Officer	Derivative	Employee Stock Option (right to buy)	500,000	$0.00	-
Jan 28, 2026	Steve Forte - Officer	Derivative	Employee Stock Option (right to buy)	325,800	$0.00	-
Footnote F1 (shares): Includes 31,510 shares of common stock underlying restricted stock units that were cancelled pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno… Full note on SEC EDGAR Footnote F2 (shares): Includes 2,000 shares acquired on August 15, 2025 under the Issuer's employee stock purchase plan. Footnote F3 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.
Jan 28, 2026	Sandra Isabelle Barros Alves - Officer	Derivative	Common Shares	31,622^{footnote F1}	-^{footnote F2}	-
Jan 28, 2026	Sandra Isabelle Barros Alves - Officer	Derivative	Employee Stock Option (right to buy)	26,000	$0.00	-
Jan 28, 2026	Sandra Isabelle Barros Alves - Officer	Derivative	Employee Stock Option (right to buy)	24,500	$0.00	-
Footnote F1 (shares): Includes 18,800 shares of common stock underlying restricted stock units that were cancelled pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno… Full note on SEC EDGAR Footnote F2 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

RPTX insider trading FAQ

What is the latest insider trade for RPTX?

Repare Therapeutics Inc. (RPTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-01-30. The full record for RPTX runs to 6 Form 4 filings, the earliest from 2026-01-29. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying RPTX stock?

No insider purchases of RPTX were filed in the last 90 days.

How many insiders are selling RPTX stock?

No insider sales of RPTX were filed in the last 90 days.

Where can I see RPTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects RPTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Jan 30, 2026 - BVF PARTNERS L P view on EDGAR
Jan 29, 2026 - Carol Schafer view on EDGAR
Jan 29, 2026 - Ann D. Rhoads view on EDGAR
Jan 29, 2026 - Thomas Civik view on EDGAR
Jan 29, 2026 - Steve Forte view on EDGAR
Jan 29, 2026 - Sandra Isabelle Barros Alves view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where RPTX's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow RPTX with a 7-day demo

RPTX on your watchlist
Every RPTX Form 4 filing on record
Up to 3 months of RPTX price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Date

Insider

Transaction

Security

Price

Value

Jan 28, 2026

BVF PARTNERS L P - 10% Owner

Other

Common Shares, no par value

5,309,432

-^{footnote F6}

Jan 28, 2026

BVF PARTNERS L P - 10% Owner

Other

Common Shares, no par value

4,308,573

-^{footnote F6}

Jan 28, 2026

BVF PARTNERS L P - 10% Owner

Other

Common Shares, no par value

548,938

-^{footnote F6}

Footnote F6 (price): The Reporting Persons received the following in exchange for each Common Share of the Issuer disposed of in connection with the Merger: $2.20 in cash per Common Share and one contingent value right per Common Share for potential cash payments.

Jan 28, 2026

Carol Schafer

Derivative

Common Shares

8,000^{footnote F1}

-^{footnote F2}

Jan 28, 2026

Carol Schafer

Derivative

Stock Option (right to buy)

37,941

$0.00

Footnote F1 (shares): Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

Jan 28, 2026

Ann D. Rhoads

Derivative

Common Shares

4,000^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

Jan 28, 2026

Thomas Civik

Derivative

Common Shares

7,500^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

Jan 28, 2026

Steve Forte - Officer

Derivative

Common Shares

56,786^{footnote F1,F2}

-^{footnote F3}

Jan 28, 2026

Steve Forte - Officer

Derivative

Employee Stock Option (right to buy)

200,000

$0.00

Jan 28, 2026

Steve Forte - Officer

Derivative

Employee Stock Option (right to buy)

85,000

$0.00

Jan 28, 2026

Steve Forte - Officer

Derivative

Employee Stock Option (right to buy)

500,000

$0.00

Jan 28, 2026

Steve Forte - Officer

Derivative

Employee Stock Option (right to buy)

325,800

$0.00

Footnote F1 (shares): Includes 31,510 shares of common stock underlying restricted stock units that were cancelled pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno… Full note on SEC EDGAR
Footnote F2 (shares): Includes 2,000 shares acquired on August 15, 2025 under the Issuer's employee stock purchase plan.
Footnote F3 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.

Jan 28, 2026

Sandra Isabelle Barros Alves - Officer

Derivative

Common Shares

31,622^{footnote F1}

-^{footnote F2}

Jan 28, 2026

Sandra Isabelle Barros Alves - Officer

Derivative

Employee Stock Option (right to buy)

26,000

$0.00

Jan 28, 2026

Sandra Isabelle Barros Alves - Officer

Derivative

Employee Stock Option (right to buy)

24,500

$0.00

Footnote F1 (shares): Includes 18,800 shares of common stock underlying restricted stock units that were cancelled pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno… Full note on SEC EDGAR
Footnote F2 (price): Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.